Impact of the International Consensus Classification of myelodysplastic syndromes

被引：7

作者：

Zhang, Yudi ^{[1
]}

Wu, Junying ^{[1
]}

Xu, Zefeng ^{[1
,2
]}

Qin, Tiejun ^{[2
]}

Qu, Shiqiang ^{[1
,2
]}

Pan, Lijuan ^{[2
]}

Wang, Huijun ^{[3
]}

Sun, Qi ^{[3
]}

Li, Chengwen ^{[3
]}

Jia, Yujiao ^{[3
]}

Cai, Wenyu ^{[3
]}

Yan, Xin ^{[1
]}

Gong, Jingye ^{[1
]}

Gao, Qingyan ^{[1
,2
]}

Li, Bing ^{[1
,2
]}

Gale, Robert Peter ^{[4
]}

Xiao, Zhijian ^{[1
,2
,3
,5
]}

机构：

[1] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Expt Hematol, Natl Clin Res Ctr Blood Dis, Haihe Lab Cell Ecosyst,Inst Hematol & Blood Dis Ho, Tianjin, Peoples R China

[2] Chinese Acad Med Sci & Peking Union Med Coll, MDS & MPN Ctr, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[3] Chinese Acad Med Sci & Peking Union Med Coll, Hematol Pathol Ctr, Inst Hematol & Blood Dis Hosp, Tianjin, Peoples R China

[4] Imperial Coll London, Haematol Res Ctr, Dept Immunol & Inflammat, London, England

[5] Chinese Acad Med Sci & Peking Union Med Coll, MDS & MPN Ctr, Inst Hematol & Blood Dis Hosp, 288 Nanjing Rd, Tianjin 300020, Peoples R China

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷 / 03期

基金：

中国国家自然科学基金;

关键词：

International Consensus Classification; myelodysplastic syndromes; prognostic; World Health Organization classification; SUBGROUP; OUTCOMES; BLASTS; MDS;

D O I：

10.1111/bjh.18628

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs study. We analysed data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria to determine the impact of the new proposal. Our analyses suggested the ICC criteria of MDS-SF3B1 identifies a more homogenous disease entity than the WHO 2016 criteria of myelodysplastic syndromes with ring sideroblasts (MDS-RS). MDS, not otherwise specified with single lineage dysplasia (MDS, NOS-SLD) patients had a better prognosis than MDS, NOS with multilineage dysplasia (MDS, NOS-MLD) patients. MDS with mutated TP53 and MDS/acute myeloid leukaemia with mutated TP53 patients had the briefest survivals. These data support the ICC of MDS, which allows more accurate diagnoses and risk stratification.

引用

页码：443 / 448

页数：6

共 50 条

[31] Prognostic classification in myelodysplastic syndromes.
Sanz, GF
Morel, P
PATHOLOGIE BIOLOGIE, 1997, 45 (08): : 617 - 626
[32] Myelodysplastic Syndromes Classification and Risk Stratification
Komrokji, Rami S.
Zhang, Ling
Bennett, John M.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 443 - +
[33] Seventh International Symposium on Myelodysplastic Syndromes
Yoshida Yataro
International Journal of Hematology, 2003, 78 (3) : 272 - 275
[34] Fourth International Symposium on Myelodysplastic Syndromes
Yoshida, Y
INTERNATIONAL JOURNAL OF HEMATOLOGY, 1997, 66 (04) : 525 - 530
[35] The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory
Frido K. Bruehl
Mazen M. Osman
Dong Chen
Joanna C. Dalland
Journal of Hematopathology, 2023, 16 : 65 - 71
[36] The new WHO and ICC classification systems for myelodysplastic syndromes and their impact on the clinical laboratory
Bruehl, Frido K.
Osman, Mazen M.
Chen, Dong
Dalland, Joanna C.
JOURNAL OF HEMATOPATHOLOGY, 2023, 16 (02) : 65 - 71
[37] A systematic classification of megakaryocytic dysplasia and its impact on prognosis for patients with myelodysplastic syndromes
Feng G.
Gale R.P.
Cui W.
Cai W.
Huang G.
Xu Z.
Qin T.
Zhang Y.
Li B.
Fang L.
Zhang H.
Pan L.
Hu N.
Qu S.
Wang J.
Cui Y.
Xiao Z.
Experimental Hematology & Oncology, 5 (1)
[38] Iron overload in myelodysplastic syndromes: A Canadian consensus guideline
Wells, Richard A.
Leber, Brian
Buckstein, Rena
Lipton, Jeffrey H.
Hasegawa, Wanda
Grewal, Kujit
Yee, Karen
Olney, Harold J.
Larratt, Loree
Vickars, Linda
Tinmouth, Alan
LEUKEMIA RESEARCH, 2008, 32 (09) : 1338 - 1353
[39] Contemporary Approach to the Diagnosis and Classification of Myelodysplastic Neoplasms/SyndromesdRecommendations From the International Consortium for Myelodysplastic Neoplasms/Syndromes (MDS [icMDS])
Aakash, Fnu
Gisriel, Savanah D.
Zeidan, Amer M.
Bennett, John M.
Bejar, Rafael
Bewersdorf, Jan Philipp
Borate, Uma M.
Boultwood, Jacqueline
Brunner, Andrew M.
Buckstein, Rena
Carraway, Hetty E.
Churpek, Jane E.
Daver, Naval G.
Dezern, Amy E.
Efficace, Fabio
Fenaux, Pierre
Figueroa, Maria E.
Garcia-Manero, Guillermo
Gore, Steven D.
Greenberg, Peter L.
Griffiths, Elizabeth A.
Halene, Stephanie
Hourigan, Christopher S.
Kim, Tae Kon
Kim, Nina
Komrokji, Rami S.
Kutchroo, Vijay K.
List, Alan F.
Little, Richard F.
Majeti, Ravindra
Nazha, Aziz
Nimer, Stephen D.
Odenike, Olatoyosi
Padron, Eric
Patnaik, Mrinal M.
Platzbecker, Uwe
Porta, Matteo G. Della
Roboz, Gail J.
Sallman, David A.
Santini, Valeria
Sanz, Guillermo
Savona, Michael R.
Sekeres, Mikkael A.
Stahl, Maximilian
Starczynowski, Daniel T.
Steensma, David P.
Taylor, Justin
Abdel-Wahab, Omar
Wei, Andrew H.
Xie, Zhuoer
MODERN PATHOLOGY, 2024, 37 (12)
[40] Prognostic Classification and Risk Assessment in Myelodysplastic Syndromes
Cazzola, Mario
Malcovati, Luca
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2010, 24 (02) : 459 - +

← 1 2 3 4 5 →